解约后，Regen要求达透医疗不得再以AestheFill产品独家经销商身份进行任何经营活动，Regen也不再 接收达透医疗发送的任何订单。 中新网北京7月25日电(赵方园)童颜针市场再起波折。 近期，江苏吴中遭爱美客子公司"解约"，首款进口童颜针的代理权发生变数。 另一端，童颜针阵营持续扩容。7月，两款童颜针接连获批上市，至此，国内童颜针获批数量已增至九 款。随着玩家渐多，童颜针还是一门好生意吗？ 童颜针代理权起纷争：江苏吴中痛失"摇钱树"？ 7月22日，江苏吴中(*ST苏吴（维权）)公告称，其控股孙公司达透医疗日前收到韩国Regen Biotech Inc. (下称：Regen)送达的《解约函》，对方明确提出解除独家经销协议，并撤销达透医疗作为AestheFill(中 文名：艾塑菲，国内首款获批进口"童颜针")产品在中国大陆地区独家经销商的所有相关授权。 据江苏吴中和爱美客双方公告，Regen给出的理由：一是达透医疗将独家经销业务实际转让给其控股股 东江苏吴中美学生物科技有限公司("吴中美学")违反协议约定；二是江苏吴中及其董事长、数名高管人 员严重违反证券法的行为，被处以相应的行政处罚，且公司上半年公告 ...

以下文章来源于聚美丽 ，作者文静 聚美丽 . 聚美丽JUMEILI.CN是中国领先的化妆品新商业媒体，为你提供新锐深度的全球化妆品商业报道，赋能化妆品品牌成长。 导语：上市首年爆卖8.5万支，首款进口童颜针归属权成谜？ 继年初10亿级功效品牌博乐达陷"权斗"后，医美相关企业又迎新争端。 值得注意的是，其中一企业系因财务造假、信息披露违规等多项违法行为，或将被终止上市的江苏吴中；而另一企业则是"医美龙头""三剑客"之 一的爱美客。 日前，这两家A股上市公司因童颜针产品代理权纠纷发生了争端。 7月21日晚，江苏吴中(*ST苏吴，600200. SH )、爱美客(300896.SZ)先后发布公告，称爱美客控股子公司REGEN Biotech, Inc.(简称：韩国 REGEN)已于2025年7月18日向江苏吴中控股孙公司达透医疗器械(上海)有限公司(简称：达透医疗)送达《解约函》，要求解除独家经销协议，并 撤销达透医疗作为艾塑菲AestheFill(下文统称：AestheFill)产品在中国大陆地区独家经销商的所有相关授权。 达透医疗将独家经销业务实际转让给其控股股东江苏吴中美学生物科技有限公司(下文简称：吴中美学 ...

继年初10亿级功效品牌博乐达陷"权斗"后，医美相关企业又迎新争端。 值得注意的是，其中一企业系因财务造假、信息披露违规等多项违法行为，或将被终止上市的江苏吴中(详见)；而另一企业则是医美龙头、三剑客之一的 爱美客。日前，这两家A股上市公司因童颜针产品代理权纠纷发生了争端。 7月21日晚，江苏吴中(证券简称：ST苏吴，证券代码600200)、爱美客(证券代码：300896)先后发布公告，称爱美客控股子公司REGEN Biotech, Inc.(下文 简称：韩国REGEN)已于2025年7月18日向江苏吴中控股孙公司达透医疗器械(上海)有限公司(下文简称：达透医疗)送达《解约函》，要求解除独家经销协 议，并撤销达透医疗作为艾塑菲AestheFill(下文统称：AestheFill)产品在中国大陆地区独家经销商的所有相关授权。 △图源：江苏吴中、爱美客公告 在此之前(2022年8月)，达透医疗得到达策国际医疗股份有限价公司(DaCe International Medical Co.,Ltd，下称：达策国际)授予，成为了艾塑菲在中国的独 家销售代理，据江苏吴中透露，独家代理权有效期至2032年8月28日。 截至今日 ...

这份解约函一旦生效，对*ST苏吴而言，无异于"釜底抽薪"。*ST苏吴自会竭尽全力阻止最坏情况的发 生，但留给它的回旋空间已相当逼仄。 Regen在解约函中的措辞相当严厉：达透医疗把手里的独家经销权"实质性转让"给其控股股东江苏吴中 美学生物科技有限公司，已属违约；吴中美学唯一股东*ST苏吴及其董事长、数名高管人员因财务造 假、信息披露违规等行为被证监会施以行政处罚，严重影响AestheFill产品在中国大陆地区的声誉。 据此，Regen要求撤销达透医疗在中国大陆的全部独家授权，且不得再以"独家经销商"身份开展任何经 营活动；Regen不再接收达透医疗发送的任何订单，已确认但未交货且已经付款的订单将及时退款。 （图片由AI生成） 爱美客最终还是送来了一纸解约函，本就因连续财务造假而站在退市边缘的*ST苏吴，如今再添致命一 击。 7月21日晚，*ST苏吴与爱美客先后发布童颜针AestheFill（中文名"艾塑菲"）独家经销权相关公告。该 产品韩国持有方Regen月初刚被爱美客收购并交出控制权，18日晚便邮件通知ST苏吴控股孙公司达透医 疗解约，要求撤销其在中国大陆对AestheFill产品独家经销的所有相关授权。 ...

6 月，新氧旗下医美机构 " 新氧青春诊所 " 推出定价 5999 元 / 支的 " 奇迹童颜 " 医美项目。 这一项目的配方中包括 340mg 艾维岚童颜针，但远低于同规格的艾维岚官方指导价 18800 元。 导语：获批上市的同类产品已有9款，另有十多家正在排队申报的童颜针。再加上有相似功效 的3款产品，竞争已趋白热化 。 " 九狼 " 围城 童颜针阵营持续扩容。 7 月 11 日，康哲药业独家代理的西宏医药的丽真然，与上海爱唯缇代理的 Olidia ，分别获得了 国家药品监督局批准。 这波新玩家的涌入，将本就激烈的市场竞争推向了新高度。 对国内首款获批的童颜针 —— 艾维岚而言，一个月前，山雨欲来的征兆已然显现。 图源：新氧青春诊所官方公众号 此举引发艾维岚 所属公司 —— 长春圣博玛生物材料（简称圣博玛）的强烈反应。随后，圣博玛 发布声明质疑新氧渠道的授权、医生培训及产品流通合规性，并提示 " 正品风险与操作隐患 " 。 童颜针是一种用于面部年轻化等美容治疗的注射产品 , 核心材料是 PLLA/PDLLA （聚乳酸）。 它主要是通过刺激皮肤自身胶原蛋白的生成来改善皮肤状态，达到皮肤嫩白、紧致的作用。 图 ...

July18,2025 Notice of Termination 智通财经记者 | 陈杨 智通财经编辑 | 谢欣 国内竞争日益激烈的再生医美针剂市场上，首款进口"童颜针"的代理权发生变数。 7月21日盘后，*ST苏吴（江苏吴中）和爱美客先后发布公告。爱美客控股子公司REGEN公司于7月18日 向江苏吴中控股孙公司达透医疗送达《解约函》，解除后者的独家经销协议，并撤销达透公司作为 AestheFill产品在中国大陆地区独家经销商所有相关授权。 解约函 TO: DATOU MEDICAL EQUIPMENT (SHANGHAI) CO. LTD. 2022年8月,根据贵司与 DACE INTERNATIONAL MEDICAL CO.,LTD 及 我司三方共同签订的《关于 AestheFill 独家销售代理权转让协议》及前期的《独 家经销协议》及修订协议(以下统称"独家经销协议"),费司取得了 AcstheFill 产品在中国大陆地区的独家经销权。但贵司及贵司的关联方在履约中出现多项违 约及违法行为,包括不限于以下: In the performance of the Exclusive Distributio ...

Core Viewpoint - Jiangsu Wuzhong (ST Suwu) faces a significant setback as its subsidiary, Datou Medical, receives a termination notice from Regen Biotech, ending their exclusive distribution agreement for AestheFill in mainland China, which may lead to a loss of market position and revenue [2][11]. Group 1: Company Developments - Jiangsu Wuzhong's subsidiary, Datou Medical, had secured exclusive rights for AestheFill in August 2022, with expectations of significant revenue contributions [5][6]. - AestheFill was projected to generate substantial profits, contributing 3.26 billion yuan in sales and 2.69 billion yuan in gross profit for Jiangsu Wuzhong in 2024 [6]. - Following the termination notice, Jiangsu Wuzhong's stock plummeted by 5.03%, reducing its market capitalization to 1.211 billion yuan [3]. Group 2: Market Context - The aesthetic medicine market, particularly the "童颜针" (youthful needle) segment, is rapidly growing, with the market size approaching 600 million yuan in 2023 [16]. - Increased competition in the market is evident, with multiple products receiving approval, intensifying the struggle for market share [16]. - The loss of AestheFill's distribution rights could significantly impact Jiangsu Wuzhong's revenue and market strategy in the aesthetic sector [16]. Group 3: Legal and Strategic Responses - Jiangsu Wuzhong has initiated a response plan and is in active communication with Regen, considering legal action to protect its interests [11][13]. - The company has publicly condemned Regen's unilateral termination of the agreement, asserting that it violates the contractual spirit and could disrupt market order [11][13].

Core Viewpoint - Jiangsu Wuzhong (ST Suwu) faces significant challenges as its subsidiary, Datou Medical, loses exclusive distribution rights for AestheFill in mainland China due to a termination notice from Regen Biotech, which may lead to a substantial decline in revenue and profits for the company [1][6]. Company Summary - Jiangsu Wuzhong's subsidiary, Datou Medical, received a termination notice from Regen Biotech, ending its exclusive distribution agreement for AestheFill, a key product in the high-end medical aesthetics market [1][3]. - The exclusive distribution agreement was initially signed in August 2022, granting Datou Medical rights until August 2032, with Regen promising no legal obstacles to the agreement [3]. - AestheFill significantly contributed to Jiangsu Wuzhong's financial recovery, with projected sales of 10 million units in 2024 and a net profit of 70.48 million yuan, marking a 197.97% increase year-on-year [3][4]. - Following the termination notice, Jiangsu Wuzhong's stock fell to 1.7 yuan per share, a 5.03% drop, reducing its market capitalization to 1.211 billion yuan [2]. Industry Summary - The medical aesthetics industry, particularly the "童颜针" (youthful injection) market, is rapidly growing, with the market size approaching 600 million yuan in 2023 [7]. - The competitive landscape is intensifying, with multiple companies vying for market share, including the recent entry of new products and brands [7]. - The loss of AestheFill's distribution rights could significantly impact Jiangsu Wuzhong's position in the medical aesthetics sector, raising concerns about its future growth and market presence [7].

Core Viewpoint - The announcement by Aimeike (300896.SZ) regarding the termination of the exclusive distribution agreement with Dato Medical Devices (Shanghai) Co., Ltd. clarifies the ownership of the AestheFill product distribution rights in mainland China, allowing for potential future sales by REGEN Biotech, Inc. [2][3] Group 1: Company Actions - Aimeike's subsidiary, REGEN Biotech, terminated the exclusive distribution agreement with Dato due to serious violations, including unauthorized transfer of distribution rights [2] - Following the termination, Dato is prohibited from operating as the exclusive distributor for AestheFill in mainland China, and REGEN will not accept any new orders from Dato [2] - Aimeike aims to enhance the AestheFill brand image and market positioning by potentially establishing a direct sales team in China [3] Group 2: Market Context - The global market for regenerative injection fillers is experiencing rapid growth, with a projected annual compound growth rate of over 30% in the next three years due to increasing consumer awareness of anti-aging products [4] - AestheFill has quickly become a leading product in the regenerative injection market, capturing nearly 30% market share in Taiwan [3][4] Group 3: Strategic Implications - The recovery of AestheFill distribution rights is expected to strengthen Aimeike's position in the aesthetic injection market and enhance its global resource integration capabilities [5] - Aimeike's comprehensive integration of AestheFill is anticipated to drive sustainable growth and long-term value creation through technological collaboration and brand revitalization [5]

Core Viewpoint - The article discusses the rapid growth and popularity of "童颜针" (youthful face injection) in the Chinese medical aesthetics market, highlighting its mechanism, market dynamics, and the competitive landscape among companies involved in this sector [6][8][22]. Market Growth - The market size of youthful face injections in China grew from approximately 100 million yuan in 2021 to over 3 billion yuan by 2024, representing a 30-fold increase in three years [6]. - Major companies like 长春圣博玛 and 爱美客 reported significant revenues from their youthful face injection products, with 长春圣博玛's "艾维岚" expected to generate over 4 billion yuan in revenue [6][24]. Product Dynamics - The core ingredient of most youthful face injections is 聚左旋乳酸 (PLLA), which stimulates collagen production in the skin [4][15]. - Different brands of youthful face injections vary in composition and pricing, with products like "濡白天使" priced around 10,000 yuan, while others like "艾塑菲" exceed 20,000 yuan [12][24]. Competitive Landscape - The entry of numerous pharmaceutical companies into the youthful face injection market has intensified competition, with over 20 companies currently registering products [30]. - The high profit margins associated with these products, with 爱美客 reporting a gross margin of 93.76% for gel-based injections, have attracted more players to the market [24][25]. Regulatory Environment - The approval of several youthful face injection products by the National Medical Products Administration (NMPA) has legitimized the market, with five products approved by 2024 [22][27]. Consumer Behavior - The article notes a growing trend among urban women to seek youthful face injections, driven by aggressive marketing and social media promotions [10][11]. - Despite the high costs, the demand for youthful face injections remains strong, with companies like 江苏吴中 achieving significant sales shortly after product launches [24][26]. Future Outlook - The global market for youthful face injections is projected to reach $1.545 billion by 2025, with a compound annual growth rate of approximately 3.8% from 2025 to 2033 [26]. - The competitive landscape is expected to evolve further, with potential price wars as more products enter the market [30].